NetworkNewsBreaks – Biocept, Inc. (NASDAQ: BIOC) Expands IP with Japanese Patent for Target Selector™ Liquid Biopsy Platform

Biocept (NASDAQ: BIOC) this morning said it has been awarded a Japanese patent covering the use of antibodies for the capture of any target of interest from any sample type on a device surface including circulating tumor cells (CTCs). The patent, entitled “Devices And Methods Of Cell Capture And Analysis,” is broader than previously issued patents owned by the company and is the 19th patent issued to Biocept related to its core liquid biopsy technology. “This is our third patent issued in Japan, strengthening the protection of our proprietary liquid biopsy technology in an important healthcare market. Expanding our intellectual property is consistent with our strategy to leverage our patent estate by licensing our technology for global distribution and commercialization,” Biocept president and CEO Michael Nall stated in the news release.

To view the full press release, visit:

About Biocept

Biocept, Inc. is a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma. The company uses its proprietary liquid biopsy technology to provide physicians with clinically actionable information for treating and monitoring patients diagnosed with cancer. The company’s patented Target Selector™ liquid biopsy technology platform captures and analyzes tumor-associated molecular markers in both circulating tumor cells (CTCs) and in circulating tumor DNA (ctDNA). With thousands of tests performed, the platform has demonstrated the ability to identify cancer mutations and alterations to inform physicians about a patient’s disease and therapeutic options. For additional information, please visit

About NetworkNewsBreak

NetworkNewsBreak (NNB) provides a rapid summary of corporate news that caught the attention of NetworkNewsWire (NNW). NNB keeps you up-to-date on active US Public Companies complementary to NNW’s broader scope as a provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published:

NetworkNewsWire (NNW)
New York, New York
212.418.1217 Office

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s